Time to first seizure ‐ generalised epilepsy Range of · adults and children with focal onset or generalised onset seizures (generalised tonic‐clonic with or without other generalised seizure…
Summary of findings: lamotrigine showed no clear difference in time to first seizure Subgroup: generalised onset seizures Range of compared with carbamazepine (low certainty).
1 finding from 1 review
Time to 12‐month remission ‐ all participants Range of · adults and children with focal onset or generalised onset seizures (generalised tonic‐clonic with or without other generalised seizure…
Summary of findings: lamotrigine showed no clear difference in time to 12‐month remission All participants Range of compared with carbamazepine (high certainty).
1 finding from 1 review
Seizure freedom · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with ≥ 75% reduction in all seizures · Lennox‐Gastaut syndrome, any age
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · Lennox‐Gastaut syndrome, any age
Lamotrigine plus ASMs leads to higher number of participants with ≥ 50% median reduction in all seizures compared with placebo plus ASMs (high certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · Lennox‐Gastaut syndrome, any age
Lamotrigine plus ASMs showed no clear difference in number of participants with adverse events leading to study… compared with placebo plus ASMs (low certainty).
1 finding from 1 review
Intervention not reported
Lamotrigine · adults and children with focal seizures
1 finding from 1 review
80% or greater reduction in seizure frequency ‐ not reported · absence seizures in children and adolescents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · absence seizures in children and adolescents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Normalisation of the EEG ‐ not reported · absence seizures in children and adolescents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Seizure freedom · absence seizures in children and adolescents
Ethosuximide leads to lower seizure freedom at 12 months compared with lamotrigine (high certainty).
1 finding from 1 review
Seizure freedom · patients with AD and epileptic seizures
It is very uncertain whether levetiracetam changes proportion with seizure freedom compared with lamotrigine (very low certainty).
1 finding from 1 review
Proportion with adverse events · patients with AD and epileptic seizures
It is very uncertain whether levetiracetam changes proportion with adverse events compared with lamotrigine (very low certainty).
1 finding from 1 review
50% or greater reduction in seizure frequency · patients with AD and epileptic seizures
It is very uncertain whether levetiracetam changes reduction in seizure frequency of 50% or more compared with lamotrigine (very low certainty).
1 finding from 1 review
Proportion with seizure freedom in dominantly inherited AD · patients with AD and epileptic seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in cognition · patients with AD and epileptic seizures
1 finding from 1 review
Change in neuropsychiatric symptoms · patients with AD and epileptic seizures
1 finding from 1 review
Improvement in quality of life · patients with AD and epileptic seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Efficacy: response (categorical) YMRS/SADS‐C decrease ≥ 50% by end of study · acute mania
The review found no eligible studies for this question.
1 finding from 1 review
Lithium for acute mania 2019 · Cochrane Headline outcomes only no estimate extracted
Studies not reported
No studies found
Efficacy: response (continuous) change in BPRS (total) from baseline to end of study ‐all data · acute mania
1 finding from 1 review